Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) saw unusually-high trading volume on Monday . Approximately 1,582,969 shares changed hands during mid-day trading, an increase of 177% from the previous session's volume of 571,061 shares.The stock last traded at $40.35 and had previously closed at $47.46.
Analyst Upgrades and Downgrades
APGE has been the subject of several analyst reports. Citigroup restated a "buy" rating on shares of Apogee Therapeutics in a research note on Monday. BTIG Research upped their price objective on Apogee Therapeutics from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Monday. Wedbush restated an "outperform" rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research note on Monday. Finally, Guggenheim restated a "buy" rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a research note on Wednesday, July 2nd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $99.00.
View Our Latest Stock Report on Apogee Therapeutics
Apogee Therapeutics Trading Down 6.6%
The firm has a market cap of $1.69 billion, a PE ratio of -10.18 and a beta of 1.47. The stock has a 50 day simple moving average of $40.38 and a 200-day simple moving average of $38.95.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. On average, equities research analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.
Insider Transactions at Apogee Therapeutics
In other news, insider Carl Dambkowski sold 10,090 shares of the firm's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $45.09, for a total transaction of $454,958.10. Following the completion of the transaction, the insider owned 238,998 shares in the company, valued at $10,776,419.82. This trade represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders sold 15,540 shares of company stock valued at $653,093. Corporate insiders own 42.77% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Brooklyn Investment Group purchased a new position in shares of Apogee Therapeutics during the first quarter valued at about $42,000. GF Fund Management CO. LTD. purchased a new position in shares of Apogee Therapeutics during the fourth quarter valued at about $43,000. AlphaQuest LLC purchased a new position in shares of Apogee Therapeutics during the first quarter valued at about $43,000. GAMMA Investing LLC grew its position in shares of Apogee Therapeutics by 3,560.1% during the first quarter. GAMMA Investing LLC now owns 5,417 shares of the company's stock valued at $202,000 after purchasing an additional 5,269 shares in the last quarter. Finally, Optimize Financial Inc purchased a new position in shares of Apogee Therapeutics during the fourth quarter valued at about $203,000. Hedge funds and other institutional investors own 79.04% of the company's stock.
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Read More
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.